All In Biotech

Drug Trial Radar · NCT05361174

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

53

Planned (sponsor's estimate)

Start

Jul 20, 2022

Primary completion

Sep 2027

Study completion Sep 2029

Sponsor

Lead sponsor
Iovance Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Conditions

  • Unresectable Melanoma
  • Metastatic Melanoma
  • Stage III Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer

Interventions

  • IOV-4001Biological

    A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Safety of IOV-4001Time frame: Up to 1 Year or depending on when the recommended phase 2 dose is determined
  2. Phase 2: Objective Response Rate (ORR)Time frame: Up to 60 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • The University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • University of Louisville

    Louisville, Kentucky · Recruiting

  • Weill Medical College of Cornell University

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.